Carcinoma

202 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Neoplasms

Narrower: Adenocarcinoma 91, Adenocarcinoma of Lung 12, Adenocarcinoma, Bronchiolo-Alveolar 2, Adenocarcinoma, Clear Cell 1, Adenocarcinoma, Mucinous 6, Adenocarcinoma, Papillary 1, Carcinoid Tumor 2, Carcinoma in Situ 7, Carcinoma, Acinar Cell 2, Carcinoma, Adenoid Cystic 6, Carcinoma, Basosquamous 1, Carcinoma, Giant Cell 2, Carcinoma, Intraductal, Noninfiltrating 6, Carcinoma, Medullary 1, Carcinoma, Neuroendocrine 3, Carcinoma, Signet Ring Cell 2, Carcinoma, Squamous Cell 72, Carcinoma, Transitional Cell 23, Cholangiocarcinoma 20, Cystadenocarcinoma, Mucinous 2, Cystadenocarcinoma, Serous 2, Eccrine Porocarcinoma 1, Klatskin Tumor 1, Paget Disease, Extramammary 3, Pseudomyxoma Peritonei 3, Squamous Cell Carcinoma of Head and Neck 65, Thyroid Carcinoma, Anaplastic 4

Treatments and conditions

Carcinoma
Treatment and conditionWhere it standsTrials
5-FU, Leucovorin, Oxaliplatin, Docetaxel for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Adebrelimab Combined With Albumin Paclitaxel for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 10 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aminolevulinic Acid 20% Topical Solution with Blue Light (dose 20 J/cm2) for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Anti-PD-1 monoclonal antibody + LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Apatinib+Camrelizumab+SOX + Preoperative Radiotherapy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
APG-157 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
ASP2998 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ASP2998 + Carboplatin + ENFORTUMAB VEDOTIN + PEMBROLIZUMAB for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Atezolizumab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Aumolertinib combined with phased chemotherapy (pemetrexed and carboplatin) for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Avelumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Axelopran + pembrolizumab for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
AZD6750 + Rilvegostomig for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Balstilimab + evofosfamide + zalifrelimab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Becotatug Vedotin for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BHB810 for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy + Histotripsy + DURVALUMAB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for adenocarcinoma, papillaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, basosquamousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for eccrine porocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biopsy Procedure + Biospecimen Collection + Computed Tomography + Laboratory Biomarker Analysis + Positron Emission Mammography + TALIMOGENE LAHERPAREPVEC + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Biospecimen Collection + Mammography + Questionnaire Administration + Random Periareolar Fine-Needle Aspiration + TAMOXIFEN + OMEGA-3-ACID ETHYL ESTERS for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMX-001 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Breast Radiotherapy for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cabozantinib + NIVOLUMAB for carcinoid tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carbon ion irradiation for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + NAB-PACLITAXEL + Cetuximab + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + CISPLATIN + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Paclitaxel for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Carboplatin + PEMBROLIZUMAB + Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CEMIPLIMAB + Gemcitabine + MOTIXAFORTIDE + NAB-PACLITAXEL for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy (preferably with a single chemotherapeutic agent) combined with capecitabine (including capecitabine monotherapy: when the preferred drug identified is capecitabine alone). for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Chemotherapy TIP for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Circulating Tumor DNA test (ctDNA test) + Dose de-escalation to contralateral neck. + Dose de-escalation to gross disease + Dose de-escalation to gross disease to contralateral neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Oral Restorative Microbiota Therapy (RMT) Capsules + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Cisplatin/pemetrexed or Carboplatin/pemetrexed + Placebo + DURVALUMAB for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Combination 5-azacytidine and nivolumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Community Treatment for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Conventional Surgery + Intensity-Modulated Radiation Therapy + Quality-of-Life Assessment + Trametinib + PEMBROLIZUMAB + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Core Biopsy + Questionnaire Administration + AFIMOXIFENE for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CP-383 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CR-002 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
cryoablation + TQB2868 Injection + Catequentinib for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
CYP Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
dabrafenib/trametinib for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dalpicilib combined with cetuximab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Dexamethasone + Prednisolone + FARLETUZUMAB ECTERIBULIN + Prednisone for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Durvalumab + Gem/Cis for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ELI-002 2P for cholangiocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eliminating RT to the elective neck for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enfortumab vedotin + pembrolizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Enzalutamide + Mevrometostat for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ERDAFITINIB + Carboplatin + CETRELIMAB + CISPLATIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Erdafitinib + cetrelimab for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Evorpacept for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for carcinoma, signet ring cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
FAPi-46 GA-68 for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + Metformin + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
FULVESTRANT + Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
GALLIUM GA-68 GOZETOTIDE for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GCP intratumoral catheter for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
GI-108 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hafnium oxide for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Haic+tae + tislelizumab + surufatinib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
High Dose Rate Brachytherapy + intra-lesional boost IMRT for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Home Health Encounter + Patient Monitoring + Questionnaire Administration + NIVOLUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LENVATINIB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Irinotecan liposomes + ADEBRELIMAB + LEUCOVORIN CALCIUM + Fluorouracil for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ivosidenib + Capecitabine + Zanidatamab + Capecitabine + FUTIBATINIB for cholangiocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Izalontamab Brengitecan for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + BEVACIZUMAB + ATEZOLIZUMAB for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Laboratory Biomarker Analysis + Pharmacological Study + Eribulin Mesylate for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
LCB84 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Lenvatinib + farletuzumab ecteribulin for adenocarcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Local Consolidation Therapy + Quality-of-Life Assessment + Radiation Therapy + Therapeutic Conventional Surgery + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Loco-regional radiotherapy for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Low Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for adenocarcinoma, bronchiolo-alveolarPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, acinar cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for cystadenocarcinoma, serousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for paget disease, extramammaryPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Positron Emission Tomography + PSMA PET Scan + Pemetrexed Disodium + PEMBROLIZUMAB for carcinoma, adenoid cysticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Medium Dose DCSZ11 + Standard Treatment for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Metformin for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mitomycin for pseudomyxoma peritoneiPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
n-dodecyl-B-D-maltoside + Cretostimogene Grenadenorepvec for carcinoma, transitional cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
N17350 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Near-infrared fluorescence imaging + Indocyanine Green for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Niacinamide for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nimotuzumab, Benmelstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Niraparib for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab + relatlimab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nivolumab and Ipilimumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Nutritional Assessment + Short-Term Fasting + Metformin hydrochloride for carcinoma, intraductal, noninfiltratingPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OK-432 for carcinoma in situPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)4
Osimertinib + Savolitinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxcel Q3W for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for adenocarcinoma, mucinousPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Paclitaxel for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Padeliporfin for carcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)5
PD-1antibody plus GEMOX for klatskin tumorPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pembrolizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Pemetrexed + AVELUMAB for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pemetrexed/Carboplatin + Pemetrexed/Cisplatin for carcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Petosemtamab for squamous cell carcinoma of head and neckPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
PF-08634404 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
PF-08634404 + ENFORTUMAB VEDOTIN for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prostate Radiotherapy + Radical Prostatectomy for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulmonary segmentectomy for adenocarcinoma of lungTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Pulsed Adaptive Radiotherapy Combined with Pembrolizumab with or without chemotherapy for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiation Therapy + OXALIPLATIN + DOCETAXEL + LEVOLEUCOVORIN + PEMBROLIZUMAB + Fluorouracil for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Radiotherapy + CISPLATIN for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Reproductive organ sparing radical cystectomy for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Rimegepant for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sacituzumab tirumotecan for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Savolitinib + Placebo for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Segmentectomy for adenocarcinoma of lungPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selective coverage radiotherapy for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Selpercatinib for carcinoma, medullaryPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Sequential cytoreductive intervention for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
SI-B003 + Izalontamab Brengitecan for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sigvotatug Vedotin for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2
SOC plus trastuzumab and pembrolizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sonesitatug Vedotin + Rilvegostomig for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Sotorasib for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Spartalizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + Bemarituzumab for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + DEPATUXIZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + NIVOLUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + RAMUCIRUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Standard cytotherapy + TRASTUZUMAB for adenocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Stereotactic Body Radiation Therapy (5 days) + Surgical Resection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Becotatug + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6002 + Enlonstobart for squamous cell carcinoma of head and neckTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + Enlonstobart for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
SYS6010 injection + PEMBROLIZUMAB for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Talimogene Laherparepvec (T-VEC) for carcinoma, squamous cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tamoxifen for carcinoma, intraductal, noninfiltratingPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
TAMOXIFEN + FULVESTRANT + ANASTROZOLE + Abemaciclib + Letrozole + IMLUNESTRANT + Tersolisib + Palbociclib + Exemestane + Ribociclib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tarlatamab for carcinoma, neuroendocrinePhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Tersolisib for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tirellizumab combined with carboplatin and albumin-paclitaxel neoadjuvant therapy+surgery for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for adenocarcinoma of lungPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for cholangiocarcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tislelizumab for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)3
Trametinib + DABRAFENIB for thyroid carcinoma, anaplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Transporter Cocktail + ZIPALERTINIB for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TTP-ICG fluorescent probe for carcinoma, transitional cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
TYRA-300 for carcinoma, transitional cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
vitamin D 25(OH)D for adenocarcinomaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
VLS-1488 for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 100 mg Tablet for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for carcinoma, adenoid cysticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
VMD-928 Tablet and Pembrolizumab (200 mg) for squamous cell carcinoma of head and neckPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vudalimab for adenocarcinoma, clear cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Vusolimogene Oderparepvec for carcinoma, squamous cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Zanzalintinib for squamous cell carcinoma of head and neckPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
zevor-cel for carcinomaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zipalertinib for carcinomaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Zolbetuximab for adenocarcinomaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.